Anti-inflammatory effect of lycopene in SW480 human colorectal cancer cells

Summary

This in vitro study examined the molecular mechanisms by which lycopene exerts anti-inflammatory effects in LPS-stimulated SW480 colorectal cancer cells. Treatment with lycopene (10–30 µM) dose-dependently suppressed mRNA expression of pro-inflammatory cytokines and mediators (TNF-α, IL-1β, IL-6, iNOS, COX-2), reduced concentrations of nitric oxide and prostaglandin E2, and inhibited NF-κB and JNK protein expression. The findings suggest lycopene acts as an inflammatory inhibitor through modulation of key signalling pathways implicated in colorectal cancer pathogenesis.

Regional applicability

This is a mechanistic laboratory study conducted in cell culture and does not directly test lycopene efficacy in human subjects or UK populations. Transferability to UK dietary recommendations or cancer prevention strategies requires human intervention or epidemiological evidence; however, the molecular findings may inform future nutritional research on lycopene-rich foods (particularly tomatoes) in the UK diet.

Key measures

mRNA expression of TNF-α, IL-1β, IL-6, iNOS, COX-2; protein expression of NF-κB, IκB, MAPK, ERK, JNK, p38; concentrations of nitric oxide (NO) and prostaglandin E2 (PGE2); cell proliferation via MTT assay

Outcomes reported

The study measured mRNA expression of inflammatory cytokines and mediators (TNF-α, IL-1β, IL-6, iNOS, COX-2) and protein expression of NF-κB and JNK in LPS-stimulated SW480 colorectal cancer cells treated with lycopene. Concentrations of nitric oxide and prostaglandin E2 were also quantified.

Topic tags